3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Colorectal Neoplasms
55
Stomach Neoplasms
27
Pancreatic Neoplasms
18
Rectal Neoplasms
16
Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
11
Neoplasm Metastasis
10
Esophageal Squamous Cell Carcinoma
8
Esophageal Neoplasms
8
Colonic Neoplasms
8
Carcinoma, Non-Small-Cell Lung
8
Carcinoma, Hepatocellular
8
Adenocarcinoma
8
Head and Neck Neoplasms
7
Gastrointestinal Neoplasms
6
Biliary Tract Neoplasms
6
Adenocarcinoma Of Esophagus
6
Ovarian Neoplasms
5
Peritoneal Neoplasms
4
Advanced Solid Tumors
4
Urinary Bladder Neoplasms
3
Nasopharyngeal Carcinoma
3
Lung Neoplasms
3
Endometrial Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Transitional Cell
3
Carcinoma
3
Breast Neoplasms
3
Appendiceal Neoplasms
3
Locally Recurrent Rectal Cancer
2
Interventions
pembrolizumab
2
darolutamide
2
relatlimab
1
olaparib
1
gedatolisib
1
enfortumab vedotin
1
Surveys and Questionnaires
1
Radiation Dose Hypofractionation
1
Pluvicto
1
Nivolumab
1
Mitomycin
1
Gemcitabine
1
Fluorouracil
1
Cisplatin
1
CP protocol
1
Blood Specimen Collection
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Male Urogenital Diseases
×
Fluorouracil
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled